These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23977933)

  • 1. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
    Soriano MM; Liao S; Danziger LH
    Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS; Juang P
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
    Morrow T
    Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
    [No Abstract]   [Full Text] [Related]  

  • 9. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fidaxomicin, a new treatment for Clostridium difficile infections.
    Epstein L; Golan Y
    Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin: first-in-class macrocyclic antibiotic.
    Mullane KM; Gorbach S
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):767-77. PubMed ID: 21810048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
    Johnson AP; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.